Association between early-life antibiotic exposure and gut microbiome alterations linked to allergic diseases in children: a systematic review Authors: F N U Sameeha, Seerat Riaz, Muhammad Nouman Aslam, Abida Perveen Published: 2025 ABSTRACT AbstractBackgroundEarly-life exposure to antibiotics has been implicated in the disruption of gut microbiota development, potentially contributing to the onset of allergic diseases in childhood. This systematic review aimed to evaluate the association between early antibiotic exposure, gut microbiome alterations, and the risk of developing allergic conditions such as asthma, atopic dermatitis, and allergic rhinitis.MethodsThis review followed PRISMA 2020 guidelines. A comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted up to [insert date]. Eligible studies included observational and interventional designs involving participants from the prenatal stage to 10 years of age. Data were extracted on antibiotic type, exposure timing, microbiome changes, and allergic outcomes. Study quality was assessed using the Newcastle–Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for randomized trials.ResultsFifteen studies involving over 1.5 million children met the inclusion criteria. The majority reported that antibiotic exposure during the prenatal period or the first two years of life was significantly associated with an increased risk of allergic diseases, particularly asthma and atopic dermatitis. Several studies also documented alterations in gut microbiota composition, including reduced Bifidobacterium and increased Clostridium and Klebsiella spps. Antibiotic type, duration, and timing of exposure were key factors influencing microbiota disruption and allergy development.ConclusionThere is growing evidence that early-life antibiotic exposure may predispose children to allergic diseases through gut microbiota disturbances. These findings support the cautious use of antibiotics during pregnancy and early childhood and underscore the need for further research into microbiota-preserving interventions and long-term outcomes.Keywords: Antibiotics, Gut microbiome, Allergic diseases, Asthma, Atopic dermatitis, Early-life exposure, Children Introduction The early stages of life are pivotal for the development of a healthy immune system, with the gut microbiome playing a central role in this process [1–16]. Colonization of the gut begins at birth and is influenced by various factors, including mode of delivery, diet, environment, and medical interventions such as antibiotic use [17]. Antibiotics, though crucial in treating infections, can indiscriminately disrupt both pathogenic and beneficial microbial populations. This disruption, known as gut dysbiosis, has been increasingly associated with adverse health outcomes, particularly in the context of immune-related conditions [18, 19]. Among these conditions, allergic diseases—including asthma, atopic dermatitis, allergic rhinitis, and food allergies—have shown a troubling rise in prevalence over recent decades. Numerous studies suggest that early-life antibiotic exposure may alter the gut microbiota in ways that impair immune regulation, potentially increasing the susceptibility to allergic sensitization and chronic inflammation. The timing, frequency, and spectrum of antibiotic use appear to be critical factors influencing the extent of microbial imbalance and subsequent immune consequences [20]. Given the widespread use of antibiotics in infancy and the growing burden of allergic diseases, it is essential to understand the long-term implications of early microbial disruption. This systematic review aims to examine the association between early-life antibiotic exposure and changes in the gut microbiome that may predispose children to allergic conditions. By synthesizing current evidence, the review seeks to provide insights that could inform antibiotic stewardship, early-life health practices, and strategies for allergy prevention. Methods Study design This study was a systematic review conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines (Fig. 1). The review was designed to summarize current evidence on the association between early-life antibiotic exposure, alterations in the gut microbiome, and the development of allergic diseases in children. PRISMA flow diagram of study selection Participants Studies included in this review involved human participants ranging from the prenatal period up to 10 years of age. The populations of interest were infants and children who had been exposed to antibiotics either during pregnancy (maternal exposure) or during early childhood. Both male and female participants were included, and studies that reported on microbiome profiles or allergic outcomes in response to antibiotic exposure were considered eligible. Eligibility criteria Studies were included if they met the following criteria: (1) observational or interventional design (e.g., cohort, case–control, cross-sectional, or randomized controlled trial), (2) evaluated early-life antibiotic exposure (prenatal or within the first years of life), and (3) reported outcomes related to either gut microbiome composition or allergic diseases such as asthma, atopic dermatitis, allergic rhinitis, or food allergy. Studies were excluded if they were reviews, case reports, editorials, conference abstracts, animal studies, or were not published in English. Search strategy A comprehensive literature search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library from inception to January 2025, using MeSH and free-text terms combined with Boolean operators. Limitations included restriction to English-language publications, exclusion of grey literature and animal studies, and reliance on full-text availability, which may have introduced language and publication bias. Moreover, the search strategy lacked granularity in reporting—such as the exact date of the final search and clearly defined inclusion and exclusion criteria—potentially limiting reproducibility and transparency. Study selection Two reviewers independently screened all retrieved titles and abstracts. Full texts of potentially eligible studies were then assessed against the inclusion and exclusion criteria. Disagreements were resolved by consensus or consultation with a third reviewer. The selection process is summarized in a PRISMA flow diagram (Fig. 1), which details the number of records identified, screened, excluded, and included. The PRISMA flowchart outlines the study selection process. A total of 81 records were identified through databases and registers, of which 16 were removed before screening. After screening 65 records and assessing 35 full-text reports for eligibility, 20 were excluded for lacking primary outcomes, population definition, or secondary outcomes. Ultimately, 15 studies were included in the final review. Data extraction Data were independently extracted by two reviewers using a standardized data extraction form. Extracted variables included author(s), year of publication, study design, number and age of participants, gender distribution, type and timing of antibiotic exposure, frequency and duration of use, reported changes in gut microbiome composition, and allergic outcomes. These data were then synthesized and organized into a comparative summary table (Table 1). Table 1Summary of included studies on early-life antibiotic exposure, gut microbiome alterations, and allergic outcomes in childrenAuthor (references)YearStudy designNo. of participantsAgeGender (male/female)Spectrum of antibioticsFrequency of antibioticsDuration of antibioticsMicrobiome changesAllergic outcomesJeffrey Ni et al. [1]2019Retrospective studyN = 2398 children1–10 years51%/48.9%Any of the Penicillin, Amoxicillin, Gentamicin, Vancomycin, Clindamycin, Sulfamethoxazole/Trimethoprim, Cephalexin, Ampicillin, Cefotaxime, Ceftriaxone, Azithromycin, Cefdinir and Ceftazidime2 exposure12 months exposure + lifetime exposureEarly and lifetime antibiotic use is strongly linked to asthma and allergic rhinitisZaira Aversa et al. [2]2021Population-based cohort studyN = 14,572 childrenN = 7546/7026Penicillins, Cephalosporins, Sulfonamides, MacrolidesMultiple times exposureFirst 2 yearsEarly antibiotic exposure increases the risk of childhood asthma, allergic rhinitis, and atopic dermatitisKiwako Yamamoto-Hanada et al. [3]2017Hospital-based birth cohort studyN = 1,550 newbornsCephem and macrolideFirst 2 yearsAntibiotic use in the first 2 years increases the risk of asthma (cephem), atopic dermatitis (macrolide), and allergic rhinitis (cephem) at age 5Courtney Hoskinson et al. [4]2024Longitudinal, prospective studyN = 34551 oral/intravenous antibiotic courseFirst year↑ tyzzerella nizilis, ↑ monosaccharides utilization and ↓ bifidobacterium and ↓ eubacterium spps. and fermentative pathwaysSystematic antibiotics are associated with atopic dermatitisYueh-Ying Han et al. [5]2017Cross-sectional studyN = 1517 children6–7 yearsAny anti- biotic + paracetamolFirst year of lifeEarly antibiotic use is associated with ↑ current wheeze and allergic rhinoconjunctivitisHang Zheng et al. [6]2022Prospective cohort studyN = 251Up to 5 years123/28Fluoroquinolones (norfloxacin, enrofloxacin, ciprofloxacin, and ofloxacin), sulfonamides (sulfamethazine, sulfamethoxazole, sulfamethoxazole, and trimethoprim), phenicols (thiamphenicol, florfenicol, and chloramphenicol), macrolides (clarithromycin, erythromycin, and azithromycin), and tetracyclineAt fetal periodEarly antibiotics uses are associated with ↑ incidence of allergic disease (asthma, atopic dermatitis, wheeze, rhinitis)Edward Mitre et al. [7]2018Retrospective cohort studyN = 131,70835 days to 1 year70,933/60775Penicillins, cephalosporins, macrolides, amoxicillin, amoxicillin clavulanate, and trimethoprim with sulfamethoxazole6 monthsIncidence of asthma, allergic rhinitis, anaphylaxis and allergic conjunctivitis are associated with antibiotic use during the first 6 months of lifeEun Lee et al. [8]2023Cohort StudyN = 789Up to 7 yearsPrenatal antibiotics exposureNo significant difference in the gut microbiota, but ↑ clostridium spp.Early antibiotic exposure is associated with childhood asthmaMarta Reyman et al. [9]2022Randomized controlled trialN = 147 infantsIntravenous antibiotics combination (penicillin + gentamicin, co-amoxiclav + gentamicin or amoxicillin + cefotaxime)First week of lifeAbundance of bifidobacterium spp. and klebsiella and enterococcus sppsBroad-spectrum antibiotics are associated with altered gut microbiotaKouta Okoshi et al. [10]2022Retrospective cohort studyN = 78,678 pregnant women0–3 yearsAny antimicrobial agent except topical antibioticsExposure during each trimesterPrenatal antibiotics exposureAntibiotic exposure during pregnancy was associated with asthma, wheezing, allergic rhinoconjunctivitis and any other allergic diseaseYu-Chuan Chang et al. [11]2023Population-based cohort studyN = 1,288,343 mother–child pairsUp to 1 yearPostnatally acetaminophenPrenatal exposure and Postnatal exposureMaternal antibiotic use during the 1 st and 2nd trimesters was positively associated with atopic dermatitis, and postnatal exposure was associated with ↑ risk of developing atopic dermatitis after 1 year of ageMike Thomas et al. [12]2006Case–control studyN = 74 (n = 37 sensitized children with wheezing and n = 37 non- sensitized children who had never wheezed3–5 yrs 1 st year of lifeEarly broad-spectrum antibiotic exposure may contribute to sensitization and wheezeSong-I Yang et al. [13]2014Prospective studyN = 7,389Antibiotics and mold exposure in infancyAntibiotic use in infancy was associated with ↑ risk of current allergic rhinitisWenjie Sun et al. [14]2015Multicenter studyN = 606 childrenMacrolideFirst year of lifeMacrolide use in the first year of life was associated with a high risk of wheezing by 36 monthsZelma Chiesa Fuxench et al. [15]2024Prospective cohort studyPenicillinIn utero and early in life exposurePenicillin was strongly associated with atopic dermatitis Summary of included studies on early-life antibiotic exposure, gut microbiome alterations, and allergic outcomes in children Quality assessment The risk of bias in observational studies was assessed using the Newcastle–Ottawa Scale (NOS), which evaluates study quality across the domains of Selection (max 4), Comparability (max 2), and Outcome (max 3) as shown in Table 2. Each study received a score out of a maximum of nine stars. Randomized controlled trials were assessed using the Cochrane Risk of Bias tool, which evaluates randomization, blinding, incomplete outcome data, and other methodological criteria. All quality assessments were conducted independently by two reviewers, and discrepancies were resolved through discussion. Table 2Risk of bias assessment using newcastle–ottawa scale (NOS)Study (Author, Year)Study designSelection (*/4)Comparability (*/2)Outcome (*/3)Total stars (*/9)Jeffrey Ni et al., 2019 [1]Retrospective************* (7/9)Zaira Aversa et al., 2021 [2]Population-based cohort**************** (8/9)Kiwako Yamamoto-Hanada et al., 2017 [3]Hospital-based birth cohort************* (7/9)Courtney Hoskinson et al., 2024 [4]Prospective cohort**************** (8/9)Yueh-Ying Han et al., 2017 [5]Cross-sectional*********(5/9)Hang Zheng et al., 2022 [6]Prospective cohort************(6/9)Edward Mitre et al., 2018 [7]Retrospective cohort**************** (8/9)Eun Lee et al., 2023 [8]Cohort************* (7/9)Kouta Okoshi et al., 2022 [10]Retrospective cohort**************** (8/9)Yu-Chuan Chang et al., 2023 [11]Population-based cohort**************** (8/9)Mike Thomas et al., 2006 [12]Case–control********* (5/9)Song-I Yang et al., 2014 [13]Prospective************ (6/9)Wenjie Sun et al., 2015 [14]Multicenter observational************ (6/9)Zelma Chiesa Fuxench et al., 2024 [15]Prospective cohort**************** (8/9) Risk of bias assessment using newcastle–ottawa scale (NOS) Data synthesis Given the heterogeneity in study designs, antibiotic types, exposure durations, microbiome assessment methods, and allergic outcomes, a meta-analysis was not appropriate. Instead, a narrative synthesis was conducted to summarize key findings. The included studies were compared qualitatively, and the data were tabulated to highlight trends in antibiotic exposure, microbiome alterations, and the development of allergic diseases in children. For consistency, dysbiosis was operationally defined as a significant reduction in microbial α-diversity (e.g., Shannon or Simpson index) or a shift in β-diversity (e.g., Bray–Curtis dissimilarity) compared to non-exposed controls, along with depletion of key taxa such as Bifidobacterium and Faecalibacterium, or overgrowth of potentially pathogenic species (e.g., Enterobacteriaceae). Results This systematic review included 15 studies comprising a total of 1,530,914 participants, ranging from small hospital-based cohorts to large national population datasets. The studies varied in design, including retrospective cohort studies, prospective cohort studies, randomized controlled trials, cross-sectional studies, and case–control studies. Participant ages ranged from the neonatal period to up to 10 years, with several studies also considering prenatal antibiotic exposure. A detailed summary of each study, including sample size, age group, antibiotic exposure characteristics, microbiome changes, and reported allergic outcomes, is presented in Table 1. A consistent trend across the majority of studies indicated that early-life antibiotic exposure is associated with an increased risk of allergic diseases, including asthma, atopic dermatitis, allergic rhinitis, wheezing, and allergic conjunctivitis [7–15]. Out of the 15 studies, 14 reported a positive association between antibiotic use and allergic outcomes [1–7, 9–15], while only one study (Eun Lee et al., 2023) found no significant microbiome alteration, though it still reported increased asthma risk [8]. Antibiotics were most commonly administered during the first year of life, though several studies assessed prenatal exposure (e.g., Kouta Okoshi et al., Yu-Chuan Chang et al., and Zelma Chiesa Fuxench et al.) [10, 11, 15]. Broad-spectrum antibiotics such as penicillins, cephalosporins, macrolides, and sulfonamides were the most frequently studied, with multiple studies suggesting a dose- and frequency-dependent relationship between antibiotic exposure and allergy risk [12–14]. Microbiome-specific findings, reported in a subset of studies, revealed that antibiotic use was often associated with decreased microbial diversity, reduction in beneficial genera such as Bifidobacterium and Eubacterium, and increased abundance of potentially pathogenic taxa like Klebsiella, Enterococcus, and Tyzzerella [1, 2]. These alterations were frequently linked to impaired immune development and pro-inflammatory responses that may contribute to allergic pathogenesis [3, 4]. The Newcastle–Ottawa Scale (NOS) assessment indicates that most included studies were of moderate to high quality, with total scores ranging from 5 to 8 out of 9. Several large population-based and prospective cohort studies, such as those by Aversa (2021), Hoskinson (2024), Mitre (2018), Okoshi (2022), Chang (2023), and Fuxench (2024), achieved the highest scores (8/9), reflecting strong selection, good comparability, and reliable outcome assessment. Moderate-quality studies scoring 6–7 stars, including those by Ni (2019), Yamamoto-Hanada (2017), Lee (2023), Zheng (2022), Yang (2014), and Sun (2015), generally showed minor limitations in comparability or outcome domains. By contrast, earlier or smaller studies such as Han (2017) and Thomas (2006) scored lower (5/9), reflecting greater risks of bias due to weaker study design or confounding. Overall, the evidence base is strengthened by several high-quality, large-scale cohort studies, though variability in study design and methodological rigor remains a limiting factor (Table 2). Subgroup analyses revealed consistent associations between early-life antibiotic exposure and increased risk of allergic outcomes, with variations by timing, antibiotic class, and outcome type. Prenatal exposure and use within the first 6–24 months of life were most strongly linked to subsequent asthma, allergic rhinitis, and atopic dermatitis, with hazard ratios and odds ratios typically ranging from 1.2 to 1.4 across studies. Notably, macrolides demonstrated stronger associations with allergic disease risk compared to β-lactams and sulfonamides, suggesting possible class-specific effects. Broad-spectrum combinations, particularly when administered in the neonatal period, were frequently associated with microbiome dysbiosis and sensitization. Across allergic outcomes, asthma and atopic dermatitis showed the most robust and consistent associations, while allergic rhinitis and anaphylaxis were less frequently reported but still demonstrated elevated risks. Overall, these subgroup findings underscore the heterogeneity of antibiotic effects, highlighting both timing- and class-dependent influences on allergy development (Table 3). Table 3Subgroup analysis of antibiotic exposure and allergy riskSubgroup categoryStudies (Ref)Exposure characteristicsAllergic outcomesEffect sizes (OR/HR/RR, 95% CI)Overall trendTiming of exposure Prenatal[8, 10, 11, 15]Maternal antibiotics (all trimesters)Asthma, wheeze, AD, rhinitisOR 1.2–1.4 (varies by outcome)↑ Risk First week of life[9]IV combinations (penicillin + gentamicin, etc.)Dysbiosis, ↑ Klebsiella/EnterococcusSignificant microbiome shifts, no direct ORDysbiosis linked to allergy First 6 months[7]Broad-spectrum (penicillins, cephalosporins, macrolides)Asthma, rhinitis, anaphylaxis, conjunctivitisHR 1.21 (1.18–1.25) asthma; HR 1.14 (1.11–1.18) rhinitis↑ Risk First 2 years[2–4, 14]Multiple classes (macrolides, cephems)Asthma, AD, rhinitis, wheezeOR 1.3–1.5 (depending on exposure)↑ Risk Beyond infancy (1–10 yrs)[1, 5, 12, 13]Broad-spectrum, any antibioticsWheeze, rhinitis, sensitizationOR ~ 1.2–1.4 reported↑ RiskAntibiotic class β-lactams (penicillins, cephs)[1, 2, 7, 10]Penicillin, amoxicillin, cephalosporinsAsthma, rhinitis, ADOR ~ 1.2–1.3 across outcomesBroad risk Macrolides[2, 3, 14]Azithromycin, erythromycin, clarithromycinAD, wheeze, rhinitisOR 1.4–1.7 (stronger effect sizes)Strong association Sulfonamides[1, 2, 6, 7]TMP-SMX and relatedAsthma, dermatitisOR ~ 1.2Moderate risk Broad-spectrum combinations[9, 12]Penicillin + gentamicin, amoxiclav + cefotaxime, etcWheeze, sensitization, dysbiosisOR ~ 1.3 (small studies)↑ Risk Fluoroquinolones/Tetracyclines[6]Norfloxacin, ciprofloxacin, tetracyclines (prenatal)Asthma, AD, rhinitisOR 1.3–1.6↑ RiskAllergic outcomes Asthma/Wheeze[1–3, 5–7, 10, 13, 14]Across infancy/prenatal exposuresConsistently reported ↑ riskHR 1.21–1.35Robust evidence Atopic dermatitis[2–4, 6, 8, 11, 15]Prenatal + early-life exposureRepeatedly linkedOR 1.3–1.6Strong evidence Allergic rhinitis/conjunct[1–3, 5, 7, 10, 13]Multiple classes/exposuresFrequently associatedOR ~ 1.2–1.4Moderate evidence Anaphylaxis[7]Early broad-spectrum exposureRare outcomeHR 1.22 (1.08–1.38)Rare but present Subgroup analysis of antibiotic exposure and allergy risk Discussion This systematic review consolidates and analyzes evidence linking early-life antibiotic exposure to alterations in gut microbiota composition and the subsequent development of allergic diseases in children. The reviewed studies collectively support the hypothesis that antibiotics administered during infancy—particularly in the first 6–12 months—can disrupt the natural development of the gut microbiome, leading to an imbalance that may adversely affect immune system maturation [7–14]. This dysbiosis often manifests as a reduction in microbial diversity, decreased abundance of key commensal bacteria such as Bifidobacterium and Lactobacillus, and an increase in potentially pro-inflammatory species such as Clostridium difficile and Escherichia coli [2–6]. These microbial shifts have been associated with a greater risk of developing conditions, such as asthma, eczema, allergic rhinitis, and food allergies [1, 15]. The gut microbiome plays a crucial role in training the immune system during early life, helping to establish a balance between immune tolerance and reactivity [21]. Beneficial microbes produce metabolites, such as short-chain fatty acids (SCFAs), that support the development of regulatory T cells (Tregs), strengthen gut barrier integrity, and modulate inflammatory responses [22, 23]. Specifically, SCFAs like butyrate promote Treg differentiation via epigenetic modifications and G-protein coupled receptor signaling, while also inhibiting pro-inflammatory pathways such as NF-κB. Antibiotic-induced reductions in SCFA-producing bacteria—particularly Bifidobacterium, Faecalibacterium prausnitzii, and Akkermansia muciniphila—may therefore interfere with these protective mechanisms, predisposing the host to heightened immune reactivity and allergic sensitization. Furthermore, the gut-lung and gut-skin axes suggest that microbial alterations in the gut can have systemic effects, contributing to allergic inflammation in distant organs such as the lungs and skin [24, 25]. Importantly, different classes of antibiotics exert varying impacts on the microbiome: broad-spectrum antibiotics tend to cause more extensive and prolonged disruption to microbial diversity and SCFA producers than narrow-spectrum agents, potentially amplifying the risk of allergic disease development. supplement analyses by stratifying allergy risks according to antibiotic class; for example, macrolides have been more strongly associated with atopic dermatitis and wheezing, while β-lactams (such as penicillins and cephalosporins) have shown broader links to asthma and allergic rhinitis. This differentiation may help clarify class-specific impacts on microbiome disruption and immune modulation. The schematic illustrates how early-life microbiome composition influences immune development and subsequent allergy risk. A diverse and balanced microbiota educates the immune system, fostering regulatory T cell (Treg) responses that promote tolerance and prevent excessive allergic reactivity. Conversely, microbial dysbiosis disrupts this balance, impairing immune regulation and driving dendritic cell (DC) signaling that promotes Th2 cell polarization and secretion of cytokines such as IL-5 and IL-13. These pathways enhance IgE production, mast cell activation, and epithelial barrier dysfunction, all of which heighten sensitivity to environmental allergens. The figure highlights the complex interplay between microbial diversity, immune education, and allergen exposure in shaping allergy susceptibility. (Fig. 2). Schematic representation of the microbiome–immune–allergy axis Importantly, this review also highlights a dose-dependent and timing-specific relationship between antibiotic exposure and allergy risk. Infants who receive multiple courses of antibiotics or are exposed to broad-spectrum agents seem to have a higher likelihood of developing allergic diseases compared to those with limited or narrow-spectrum use [2]. The timing of exposure is equally critical; antibiotics administered during the neonatal period or within the first six months of life appear to have a more profound and lasting impact on microbiota composition and immune outcomes [6–11, 13, 15]. These findings emphasize the existence of a “window of vulnerability” during which the developing microbiome is especially sensitive to external perturbations. Despite these findings, the current body of literature has several limitations. Most studies are observational and thus cannot definitively establish causality. Confounding factors—such as maternal health, mode of delivery, breastfeeding practices, and the underlying infections that necessitated antibiotic use—can complicate interpretations. Additionally, variability in microbiome analysis techniques, outcome definitions, and follow-up durations contribute to heterogeneity across studies. While animal models provide valuable mechanistic insights, translating these findings to human populations remains complex due to species-specific immune and microbial differences [26]. Nevertheless, the overall direction of evidence underscores the importance of judicious antibiotic use during infancy. Healthcare providers should weigh the potential long-term consequences of early antibiotic exposure against the immediate need for treatment, especially in non-severe cases or when alternative approaches are available [27]. For instance, in acute otitis media (AOM)—a common childhood infection—watchful waiting may be appropriate in mild, non-complicated cases, particularly in children over two years of age, thereby reducing unnecessary antibiotic exposure. Conversely, group B Streptococcus (GBS) prophylaxis during labor, although involving intrapartum antibiotic use, remains critical for preventing neonatal sepsis; in such cases, the benefits outweigh potential microbiome disturbances. Furthermore, interventions aimed at restoring microbial balance—such as the use of probiotics, prebiotics, or even fecal microbiota transplantation (FMT)—show promise in mitigating antibiotic-induced dysbiosis, although their effectiveness in preventing allergic diseases remains to be conclusively established [28]. This systematic review has several limitations. Most included studies are observational, limiting the ability to infer causality between early-life antibiotic exposure, gut microbiome alterations, and allergic disease development. Many are subject to confounding factors—such as underlying infections, delivery mode, feeding practices, genetic predisposition, and environmental exposures—that may independently affect both antibiotic use and allergy risk. A systematic summary of how these confounders were adjusted for is lacking, which weakens the specificity of the associations observed [36]. Moreover, considerable heterogeneity exists across studies in terms of design, populations, timing and type of antibiotic exposure, microbiome assessment methods, and outcome definitions, making comparisons difficult. Publication bias may be present, favoring studies with positive findings, and variable follow-up durations further limit insights into long-term effects beyond early childhood [37]. Future research should prioritize longitudinal cohort studies and randomized controlled trials to clarify causal relationships and elucidate underlying mechanisms. There is also a need for standardized methodologies in microbiome research to enable better comparisons across studies [29]. Understanding the interplay between host genetics, microbial ecology, and environmental exposures will be key to developing targeted strategies for allergy prevention [30]. Ultimately, this line of research has the potential to inform public health policies and pediatric clinical practices, helping to curb the rising prevalence of allergic diseases through microbiome-informed early-life care [31]. Conclusion This systematic review highlights a consistent association between early-life antibiotic exposure and an increased risk of developing allergic diseases in children, including asthma, atopic dermatitis, and allergic rhinitis. The findings suggest that antibiotics, particularly when administered during critical windows such as the prenatal period and the first two years of life, can significantly alter the composition and function of the gut microbiome. These alterations may impair immune system development, promoting allergic sensitization and disease [32]. Although the specific microbial changes varied across studies, several reported a reduction in beneficial bacteria like Bifidobacterium and an increase in potentially pathogenic taxa, alongside functional disruptions in fermentative and metabolic pathways [33]. Despite the variability in study designs, populations, and antibiotic types, the cumulative evidence underscores the need for cautious antibiotic prescribing practices in early childhood and during pregnancy. Clinicians and policymakers should consider the long-term immunological consequences of antibiotic exposure in early life, especially given the rising global burden of allergic diseases [34]. Future research should focus on elucidating the exact microbial mechanisms involved, exploring potential protective strategies (such as probiotics or microbiota-targeted therapies), and establishing standardized methods for measuring microbiome and allergy outcomes [35]. Author contributions A.B. and C.D. wrote the main manuscript text and A.D prepared Figs. 1and 2 and Table 1 and 2. All authors reviewed the manuscript. Funding The authors received no specific funding. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.